Company record
Neurocrine Biosciences, Inc. concentrates on creating biopharmaceutical products for disorders of the nervous system, covering neurological, neuroendocrine and neuropsychiatric conditions. Its pipeline comprises a variety of agents, including enzyme inhibitors, antagonists and receptor‑blocking molecules. At present, it provides therapeutic options for tardive dyskinesia, Huntington’s chorea, endometriosis, uterine fibroids and congenital adrenal hyperplasia. Core competencies extend from early‑stage drug discovery through clinical testing to market launch, and the firm operates within the broader healthcare sector.
This directory record does not yet have a linked material-flow brief.